Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Cash Flow: 2015-2024

Historic Net Cash Flow for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$37.6 million.

  • Intellia Therapeutics' Net Cash Flow rose 459.45% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 256.22%. This contributed to the annual value of -$37.6 million for FY2024, which is 87.27% up from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Net Cash Flow is -$37.6 million, which was up 87.27% from -$295.1 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Net Cash Flow ranged from a high of $410.0 million in FY2022 and a low of -$295.1 million during FY2023.
  • In the last 3 years, Intellia Therapeutics' Net Cash Flow had a median value of -$37.6 million in 2024 and averaged $25.8 million.
  • Per our database at Business Quant, Intellia Therapeutics' Net Cash Flow skyrocketed by 6,687.73% in 2020 and then slumped by 171.98% in 2023.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Net Cash Flow stood at $107.4 million in 2020, then slumped by 136.43% to -$39.1 million in 2021, then spiked by 1,148.00% to $410.0 million in 2022, then slumped by 171.98% to -$295.1 million in 2023, then soared by 87.27% to -$37.6 million in 2024.